Cao et al. The peak expiratory flow rates and rhinitis symptoms in the SLIT group improved, and the medical score of asthma significantly decreased. Furthermore, no severe adverse events occurred in the trial, and the most common adverse events were mild asthma and local rash. However, SLIT is not always a safe alternative to subcutaneous therapy. Shortness of breath, wheezing and severe asthma attacks have also been reported, yet SLIT is now accepted by the World Health Organization as a valid alternative to subcutaneous therapy in children.
The review written by Larenas-Linnemann discusses the shortcomings of SLIT in terms of efficacy, dosing, timing of treatment and patient selection, which all need to be taken into serious consideration. Evidence for beneficial effects from SLIT has been confirmed in children with allergic rhinitis , , or asthma caused by pollen exposure. SLIT was also found to prevent the progression from allergic rhinitis to asthma.
The use of different allergens, optimal doses, duration of treatment and the application in children or adults should be further examined for SLIT. In this clinical trial, SLIT with monomeric allergoids produced clinically significant results across a wide range of doses. The absence of significant side effects, even at high doses, was probably due to the low level of allergenicity.
For immunotherapy of atopic dermatitis, SCIT is not indicated for use because of the likelihood that it could induce exacerbations of manifest atopic dermatitis or relapses of latent atopic dermatitis. The putative value of SIT is not only in its use as a causal therapy for already manifest sensitizations, but also in its use as a preventive measure to avoid the development of further sensitizations and to counteract the atopic march early in life.
This is of particular importance in light of recent developments that provide clear evidence for a genetically determined skin barrier dysfunction that predisposes a subgroup of patients with atopic dermatitis to the manifestation of numerous sensitizations and concomitant asthma.
Many gene-based strategies for immunotherapy aimed at reversing or preventing abnormal immune regulation and restoring Th1-predominated responses or regulatory T cell function have been developed, , , , , but therapeutic efficacy depends highly on delivery efficiency and target selection. SLIT is a better choice for prophylactic and therapeutic approaches to allergy treatment, but the outcomes for allergic disease from the use of different sensitizing allergens will still need further definition.
Also, a challenge remains in evaluating whether results from experimental animal studies will hold true in humans. Continuous improvements have been made in allergen preparation, such as the introduction of highly purified allergoids and recombinant allergens, the targeting of dominant T-cell epitopes of allergen, 12 , 45 and the refinement of treatment schedules, as well as in the concomitant use of adjuvants.
The collection of data from large, well-designed, double-blind, placebo-controlled, randomized trials with post-treatment follow-up, will provide robust substantiation of current evidence. SCIT has demonstrated long-term clinical effects and the potential to preventing the development of asthma in children with allergic rhinoconjunctivitis for up to 7 years after treatment termination.
Mucosal immunotherapy studies in adults and children with allergic diseases that use different types of allergens and different routes of administration and evaluate the side effects from each route will improve our knowledge on this issue. We anticipate that continued growth in the understanding of imunotherapeutic strategies for allergic diseases will offer therapies with lower doses, greater safety and more effective application in the future.
Too clean, or not too clean: the hygiene hypothesis and home hygiene. Clin Exp Allergy ; 36 : — Togias A. Mechanisms of nose-lung interaction. Allergy ; 54 Suppl 57 : 94— PubMed Google Scholar. United airways disease: therapeutic aspects.
Thorax ; 55 Suppl 2 : S26—S The nose—lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol ; 1 : 7— Allergy ; 63 Suppl 86 : 8— The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy ; 57 : — The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res ; 3 : 67— J Allergy Clin Immunol ; : — Overview of the treatment of allergic rhinitis and nonallergic rhinopathy.
Proc Am Thorac Soc ; 8 : — Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol ; 65 : — Papi A. Treatment strategies in mild asthma. Curr Opin Pulm Med ; 15 : Pedersen S. Do inhaled corticosteroids inhibit growth in children? Severe asthma treatment: need for characterising patients. Lancet ; : — Wenzel S. Severe asthma in adults.
Recent advances in the development of anti-allergic drugs. Allergol Int ; 55 : 35— Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature ; : — Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology.
Ann Allergy Asthma Immunol ; 81 : — Murine model of oral tolerance. Induction of Fas-mediated apoptosis by blockade of interleukin Ann NY Acad Sci ; : — IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis.
Eur J Immunol ; 28 : — Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev ; : — Injection allergen immunotherapy for asthma. Google Scholar. Allergen immunotherapy. Mayo Clin Proc ; 82 : — Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study.
Allergy ; 61 : — Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med ; 11 : S45—S Pulmonary dendritic cells producing IL mediate tolerance induced by respiratory exposure to antigen. Nat Immunol ; 2 : — Schroder NW. The role of innate immunity in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol ; 9 : 38— Holgate ST. Pathogenesis of asthma. Clin Exp Allergy ; 38 : — Airway inflammation induced after allergic poly-sensitization can be prevented by mucosal but not by systemic administration of poly-peptides.
Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol ; 3 : — Oral tolerance. Immunol Res ; 28 : — Mayer L, Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol ; 4 : — T cell anergy and costimulation. The puzzling world of murine T regulatory cells. Microbes Infect ; 4 : — Groux H. Type 1 T-regulatory cells: their role in the control of immune responses.
Transplantation ; 75 : 8S—12S. Immunol Rev ; : 18— Thorstenson KM, Khoruts A. J Immunol ; : — Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL, Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. J Leukoc Biol ; 74 : — Wan YY.
Regulatory T cells: immune suppression and beyond. Cell Mol Immunol ; 7 : — Clin Exp Allergy ; 29 : — Wiedermann U. Prophylaxis and therapy of allergy by mucosal tolerance induction with recombinant allergens or allergen constructs. Curr Drug Targets Inflamm Allergy ; 4 : — Vaccination with genetically engineered allergens prevents progression of allergic disease. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice.
J Exp Med ; : — Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice. Int J Immunopathol Pharmacol ; 23 : — Allergol Immunopathol Madr ; 33 : — CAS Google Scholar. A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance.
Cholera toxin B suppresses allergic inflammation through induction of secretory IgA. Mucosal Immunol ; 2 : — Immunomodulatory effects of CpG oligodeoxynucleotides on house dust mite-induced airway inflammation in mice. Int Arch Allergy Immunol ; : 6— Krieg AM. CpG motifs in bacterial DNA and their immune effects.
Annu Rev Immunol ; 20 : — CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev ; 61 : — Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs.
Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest ; : — Ramaprakash H, Hogaboam CM. Intranasal CpG therapy attenuated experimental fungal asthma in a TLR9-dependent and -independent manner. Int Arch Allergy Immunol ; : 98— Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. Geneva: January 27—29 Allergy ; 53 Suppl 44 : 1— Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses.
Vaccine ; 18 : — Vollmer J. Expert Opin Biol Ther ; 5 : — Production, properties, and some new applications of chitin and its derivatives. Crit Rev Food Sci Nutr ; 43 : — Advances in Chitin and Chitosan. New York: Elsevier Applied Science, Burton OT, Zaccone P.
The potential role of chitin in allergic reactions. Trends Immunol ; 28 : — Oral administration of chitin down-regulates serum IgE levels and lung eosinophilia in the allergic mouse. Intranasal application of chitin microparticles down-regulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy.
Clin Exp Allergy ; 32 : — Acidic mammalian chitinase in asthmatic Th2 inflammation and IL pathway activation. Science ; : — Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature ; : 92— Lee CG. Chitin, chitinases and chitinase-like proteins in allergic inflammation and tissue remodeling.
Yonsei Med J ; 50 : 22— Tsigos I, Bouriotis V. Purification and characterization of chitin deacetylase from Colletotrichum lindemuthianum. J Biol Chem ; : — Angelova N, Hunkeler D. Effect of preparation conditions on properties and permeability of chitosan—sodium hexametaphosphate capsules. J Biomater Sci Polym Ed ; 12 : — The effect of water-soluble chitosan on macrophage activation and the attenuation of mite allergen-induced airway inflammation.
Biomaterials ; 29 : — Probiotics and immunity. J Gastroenterol ; 44 : 26— Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol ; 94 : — Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma.
Clin Exp Allergy ; 37 : — Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice. The role of the intestinal microbiota in the development of atopic disorders. Allergy ; 62 : — Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis.
Effect of fermented milk prepared with two probiotic strains on Japanese cedar pollinosis in a double-blind placebo-controlled clinical study. Int J Food Microbiol ; : — Improvements in seasonal allergic disease with Lactobacillus plantarum No. Biosci Biotechnol Biochem ; 74 : — Probiotics and prebiotics: clinical effects in allergic disease. Curr Opin Pediatr ; 22 : — Synbiotics reduce allergen-induced T-helper 2 response and improve peak expiratory flow in allergic asthmatics.
Allergy ; 66 : 39— High intestinal IgA associates with reduced risk of IgE-associated allergic diseases. Pediatr Allergy Immunol ; 21 Pt 1 : 67— Probiotics and allergy in children—an update review. Pediatr Allergy Immunol ; 21 : e—e Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice.
Clin Exp Allergy ; 30 : — Recent advances in immunotherapy of allergic rhinitis. Curr Allergy Asthma Rep ; 8 : — Int Immunol ; 11 : — Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit.
Scand J Immunol ; 71 : 1— Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. Hussain I, Kline JN. DNA, the immune system, and atopic disease. J Investig Dermatol Symp Proc ; 9 : 23— CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma.
BioDrugs ; 24 : — Local nasal immunotherapy: efficacy of Dermatophagoides farinae —chitosan vaccine in murine asthma. Int Arch Allergy Immunol ; : — Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy ; 64 : — Induction of Th1-type immune response by chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen Der p 2 for oral vaccination in mice. Cell Mol Immunol ; 6 : 45— Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice.
Vaccine ; 21 : — The effect of oral feeding of Lactobacillus casei strain Shirota on immunoglobulin E production in mice. J Dairy Sci ; 81 : 48— Lactobacillus casei strain Shirota suppresses serum immunoglobulin E and immunoglobulin G1 responses and systemic anaphylaxis in a food allergy model. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine ; 22 : 87— Recombinant Lactobacillus plantarum inhibits house dust mite-specific T-cell responses.
Clin Exp Immunol ; : 2—8. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. A potential immunotherapy approach: mucosal immunization with an IL peptide-based virus-like particle vaccine in a mouse asthma model. Vaccine ; 25 : — Genet Vaccines Ther ; 1 : 3.
Intranasal coadministration of live lactococci producing interleukin and a major cow's milk allergen inhibits allergic reaction in mice. Clin Vaccine Immunol ; 14 : — ILinducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Gene vaccination: plasmid DNA is more than just a blueprint.
Immunol Today ; 19 : 89— Effect of oral tolerance in a mouse model of allergic rhinitis. Otolaryngol Head Neck Surg ; : — Oral administration of allergen extracts from Dermatophagoides farinae desensitizes specific allergen-induced inflammation and airway hyperresponsiveness in rats.
Int Immunopharmacol ; 8 : — J Autoimmun ; 20 : — Mucosal administration of IL enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int Immunol ; 13 : — Modulation by cytokines of induction of oral tolerance to type II collagen. Arthritis Rheum ; 42 : — Flt-3 ligand reverses late allergic response and airway hyper-responsiveness in a mouse model of allergic inflammation.
Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and ILproducing properties. Oral administration of grass pollen to hay fever patients.
An efficacy study in oral hyposensitization. Allergy ; 40 : — Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol ; 80 : — Canonica GW, Passalacqua G. This strategy also allows much higher quantities of allergen to be administered safely, which may be an important factor for tolerance induction. Allergen variants with hypoallergenic activity following chemical modification are already in clinical practice. Allergoids are hypoallergenic, but IgE epitopes are not fully destroyed and they still retain the risk of anaphylaxis.
The fusion of major allergens then expressed as a recombinant has also been shown to be effective and potentially safer. Other systems used to decrease the binding efficiency of B cell epitopes while preserving T cell epitopes include the generation of chimeric, polymeric or unrefolded molecules, by fusion of fragments of allergen, or polymerization and denaturation of major allergen, respectively.
T cell epitope vaccination has been most successful with allergen products containing one or a few major allergens, such as cat dander, but even then there will be rare individuals whose MHC haplotype precludes their T cells from recognizing the particular epitopes in a vaccine.
A compromise is simply to fragment the allergens into small peptides. In some studies synthetic DNA sequences that contain CpG and the glycolipid monophosphoryl lipid A were used as a Th1-inducing adjuvant in association with allergen for subcutaneous immunotherapy in ragweed and grass allergic patients.
Although limited data support the effectiveness and safety of this approach, confirmatory studies are needed. An alternative solution is to produce recombinant allergens at defined concentrations and in complete purity to produce vaccines which would then be universally standardized.
While this has been achieved successfully for some mixtures of allergens, it is still problematic when extracts comprise many major and minor allergens. Although attractive in terms of allergen standardization, this strategy is likely to be expensive and not necessarily of therapeutic advantage. Humanized monoclonal anti-IgE antibody, omalizumab, is available for use in moderate-severe allergic asthma.
Omalizumab is well tolerated and has been shown to reduce the requirement for inhaled corticosteroids and the risk of asthma exacerbations Moreover, omalizumab is able to reduce circulating levels of free IgE, inhibit early- and late-phase responses to allergen, and reduce eosinophils, lymphocytes and IL producing cells in tissues. Therefore a combination of anti-IgE therapy and allergen immunotherapy might offer advantages that neither method provides separately. Intralymphatic allergen administration is an alternative route of SIT that may potentially be safe and effective.
Absence of mast cells in lymph nodes potentially eliminates the risk of anaphylaxis. A short updosing protocol for intralymphatic treatment 3 injections in 8 weeks has been shown to suppress target organ responses in the nose and has potential to improve patient compliance in view of the lower risk of adverse events and a shortened protocol of injections compared with conventional SCIT.
Figure 1. In contrast, high-allergen exposure that occurs with immunotherapy results in a shift of T cell polarization. These altered T cell responses contribute to the induction of allergen-specific IgG, and in particular IgG4 antibody responses, and also an increase in IgA. There is good evidence that these mechanisms operate for immunotherapy via both the subcutaneous and sublingual routes. It is likely that for SLIT there are additional local mechanisms involving interactions between recirculating dendritic cells and T cells in the regional lymph glands and nasal mucosa — since the cervical lymph chain serve both the nasal mucosa and the floor of the mouth.
Previously published online: www. Hum Vaccin Immunother. Published online Oct 1. Antonio Cappella and Stephen R. Author information Article notes Copyright and License information Disclaimer. Durham; Email: ku. This article has been cited by other articles in PMC. Abstract Allergen specific immunotherapy involves the repeated administration of allergen products in order to induce clinical and immunologic tolerance to the offending allergen. Keywords: adjuvant, allergen vaccine, immunopotentiator, sublingual immunotherapy, vector system.
Introduction Allergen immunotherapy also termed hyposensitization therapy, immunologic desensitization involves the gradual administration of increasing amounts of allergen to which the patient is sensitive, for the purpose of modulating the immune response to that allergen and alleviating allergic symptoms. Table 1. Open in a separate window. Safety of SCIT All preparations that are currently available standardized extract, allergoids and recombinant allergen may trigger side effects.
There have been 5 isolated reports worldwide of anaphylaxis following sublingual treatment reported below and Table 4 Table 4. Individual case reports of anaphylaxis after SLIT treatment. Sublingual Immunotherapy Efficacy in rhinitis and asthma SLIT involves the regular self-administration of allergen extract prepared as drops or tablets that are retained under the tongue for 1—2 min and then swallowed.
Table 2. One of the trials investigated the efficacy of grass and birch pollen immunotherapy. Table 3. Summary of meta-analyses for SLIT. Safety of sublingual immunotherapy One of the purported advantages of SLIT over SCIT is greater safety, which permits the administration of this treatment outside of the medical setting. Long-term efficacy Recently data have highlighted specific immunotherapy not only as an effective therapeutic agent but also as having disease modifying properties, inducing disease remission.
Table 5. Seasonal rhinoconjunctivitis symptom and medication scores during 5 y treatment with grass pollen allergy tablet sublingual immunotherapy. Mechanism of immunotherapy Studies have confirmed a reduction in target organ sensitivity in the skin, conjunctiva, nose and lung after immunotherapy 66 - 68 including inhibition or early and late responses. Immunoglobulin responses During immunotherapy for seasonal pollinosis there is an Initial increase of serum allergen-specific IgE without apparent ill effects, followed by blunting of seasonal increases in IgE.
Sublingual Immunotherapy The oral mucosa is a site of natural immune tolerance induction. Serum immunoglobulin responses during SLIT During SLIT for seasonal pollinosis, there is a paradoxic increased in allergen-specific IgE, followed by blunting of seasonal increases in serum IgE without any apparent association with adverse events. Subcutaneous vs. Predictive biomarkers for clinical response Careful patient selection and early identification of responders is necessary in order to target intervention at those who will benefit and to exclude those who are less likely to respond to immunotherapy.
Novel approaches to allergen immunotherapy Allergen immunotherapy is currently performed with crude allergen extracts that usually contain non allergenic and potentially toxic unwanted proteins, which may possibly induce side effects on therapeutic administration.
Acknowledgments Dr. Disclosures Dr. Footnotes Previously published online: www. References 1. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol. Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol. Clin Exp Allergy. Noon L. Prophylactic inoculation against hay fever. Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injecton therapy in ragweed hay fever.
N Engl J Med. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy. Black JH. The oral administration of pollen. J Lab Clin Med. The oral administration of pollen: clinical report. Committee on the safety of medicines.
CSM update. Desensitizing vaccines. World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. World Health Organization. GA 2 LEN. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial.
Immunotherapy in asthma: an updated systematic review. Specific immunotherapy in asthma. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in children with allergic asthma.
J Investig Allergol Clin Immunol. Injection allergen immunotherapy for asthma. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. Allergen immunotherapy: therapeutic vaccines for allergic diseases.
A WHO position paper. Sublingual immunotherapy for allergic rhinitis. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. SLIT Study Group Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials.
Ann Allergy Asthma Immunol. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol Madr ; 18 — Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract D. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study.
Pediatr Pulmonol. Blaiss M, Maloney J. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis.
The safety of sublingual-swallow immunotherapy: an analysis of published studies. Sublingual immunotherapy: a comprehensive review. The safety of sublingual immunotherapy with one or more allergens in adults. Sublingual immunotherapy: where do we stand? Present and future. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy.
Anaphylaxis to sublingual immunotherapy. Anaphylaxis by latex sublingual immunotherapy. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract.
Duration of the efficacy of immunotherapy after its cessation. A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects. A double-blind study of the discontinuation of ragweed immunotherapy. Long-term clinical efficacy of grass-pollen immunotherapy.
Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. The PAT investigator group Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: year follow-up on the PAT study. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood.
Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a year prospective study. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. Missing Reference Info. Long-lasting effects of sublingual immunotherapy according to its duration: a year prospective study.
Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. The effect of immunotherapy on the cutaneous late phase response to antigen. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios.
Scadding G, Durham S. Mechanisms of sublingual immunotherapy. J Asthma. IL and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. Impaired secretion of interleukin-4 and interleukin by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and jun B: relevance to immunotherapy.
Mechanisms of immunotherapy to aeroallergens. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med. Role of interleukin 10 in specific immunotherapy. IL inhibits cytokine production by activated macrophages.
J Immunol. Interleukin 10 IL inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL produced by monocytes. Int Immunol. Human IL is produced by both type 1 helper Th1 and type 2 helper Th2 T cell clones and inhibits their antigen-specific proliferation and cytokine production.
Grass pollen immunotherapy: IL induction and suppression of late responses precedes IgG4 inhibitory antibody activity. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression.
J Clin Immunol. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Measurement of IgE antibodies against purified grass pollen allergens Lol p 1, 2, 3 and 5 during immunotherapy. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. The IgG subclasses of antibodies to grass pollen allergens produced in hay fever patients during hyposensitization.
Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Modifications in IgG subclasses in the course of immunotherapy with grass pollen. Inhibition of rBet v 1-induced basophil histamine release with specific immunotherapy -induced serum immunoglobulin G: no evidence that FcgammaRIIB signalling is important.
Grass pollen immunotherapy induces mucosal and peripheral IL responses and blocking IgG activity. Inhibition of CDdependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells.
Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Monitoring allergen Immunotherapy Mechanisms of immunotherapy to aeroallergens of pollen-allergic patients: The ration of allergen-specificIgG4 to IgG1 correlates with clinical outcome. The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?
Sahiner, E. Civelek, A. Tuncer et al. Zitelli K. Evidence-based evaluation and management of chronic urticaria in children. Caffarelli, B. Cuomo, F. Cardinale et al. Pite, B. Wedi, L. Borrego et al. IgE-mediated food allergy in children. Novembre, A. Cianferoni, F. Mori et al. Greaves M. Monfrecola, E. Masturzo, A.
Riccardo et al. Luong K. Allergy Asthma Immunol. Imbalzano, M. Casciaro, S. Quartuccio et al. Minciullo, A. Cascio, G. Barberiet al. Wustlich, R. Brehler, T. Luger et al. Akelma, M. Cizmeci, E. Mete et al. Kolkhir, G. Balakirski, H. Merket al. Hill D. Philadelphia, ChurchillLivingstone, Khan, M.
Konstantinou, R. Asero, M. Ferrer et al. Sabroe, P. Seed, D. Francis et al. Gaig, P. Garcia-Ortega, E. Enrique et al. Zauli, G. Deleonarid, S. Goderaro et al. Kowalski M. Grattan, D. Francis, N. Slater et al. A Popular myth — low-histamine diet improves chronic spontaneous urticaria— fact or fiction?
Wagner, D. Dirk, A. Peveling-Oberhag et al. Weller, E. Ardelean, E. Scholzet al. Vonakis B. Church, M. Maurer, F. Simons et al. Bousquet, N. Khaltaev, A. Cruz et al. Suppl P. Staevska, T. Popov, T. Kralimarkova et al. Siebenhaar, F. Degener, T. Zuberbieret al. Gimenez-Arnau A. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. Ortega Fernandez de Retana A.
Lezaun Alfonso A. Anisakis simplex is a common parasite in fish and cephalopods and is not only capable of causing anisakiasis in humans through visceral invasion of the third-stage larvae but can also cause anaphylactic reactions, as has recently been demonstrated. We present the clinical case of a year-old man who initially presented anaphylactic reactions related to eating fish.
Shortly afterwards, he began to experience self-limiting recurrences of very intense epigastric pain, nausea and vomiting. Skin tests for immediate hypersensitivity prick tests with a commercial extract as well as the determination of specific IgE in the patient's serum were clearly positive for A. The hemogram did not show eosinophilia. Copro-cultures and parasites in the patient's feces were repeatedly negative.
Gastroscopy was normal. The intestinal tract showed contrast flocculation and dilation of ansas in the distal duodenum and proximal jejunum. Biopsy samples of gastric and distal duodenum mucous showed an active process of chronic inflammation with a predominance of eosinophils in the lamina propria. After subjecting the patient to a fish and cephalopod-free diet and treating him with thiabendazole mg every 12 hours for 6 days, he showed no sign of symptoms while awaiting new tests.
|J investing allergol clin immunol issn lookup||Value investing valuation methods|
|Better to pay down mortgage or invest||There have been few reports of probiotic supplementation in small numbers of patients with chronic urticarial [ 11122627 ]. Immunol Rev ; : — In the first randomized controlled trial of the sublingual SLIT was published. The role of innate immunity in the pathogenesis of asthma. Kern J, Bielory L. Compared to acute urticaria, chronic disease is more complexly associated with imbalances in immunity, inflammation and coagulation [ 2 ]. These symptoms develop quickly within minutes after ingestion and only last minutes.|
|Forex academy webinars||Usd/rub pip value in forex|
|Isik fx forex factory||The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. The prevalence of near fatal reactions in this meta-analysis were reported as 1 in 1. It is likely that for SLIT there are additional local mechanisms involving interactions between recirculating dendritic cells and T cells in the regional lymph glands and nasal mucosa — since the cervical lymph chain serve both the nasal mucosa and the floor of the mouth. Ethics approval and consent to participate Ethics approval and consent to participate are not applicable to this review article. Sublingual immunotherapy to house dust mite in pediatric patients with allergic rhinitis and asthma: a retrospective analysis of clinical course over a 3-year follow-up period.|
|Abdominal thrusts are not effective forex||Crameri R, Rhyner C. Mucosal immunotherapy is an ideal choice based on these considerations. One study 21 assessed the effects of specific immunotherapy as an add-on to pharmacologic treatment and allergen avoidance, in patients with mild-to-moderate asthma and allergy to house dust mite. Table 2 Efficacy on chronic urticaria in the experiment group and the placebo group. There is good evidence that these mechanisms operate for immunotherapy via both the subcutaneous and sublingual routes.|
Clin Haematol. Penicillin hypersensitivity with eosinophilia: a case report with immunologic studies. Am J Med. Two cases of toxic epidermal necrolysis caused by delayed hypersensitivity to beta-lactam antibiotics. J Investig Allergol Clin Immunol. Drug related myocarditis: I. Hypersensitivity myocarditis. Hum Pathol. Eosinophilic cholecystitis, appendiceal inflammation, pericarditis, and cephalosporin-associated eosinophilia.
Dig Dis Sci. Verma S, Kieff E. Cephalexin-related nephropathy. Cephalexin associated pulmonary infiltration with circulating eosinophilia. Marik PE, Ferris N. Delayed hypersensitivity reaction to vancomycin. Vancomycin-induced toxic epidermal necrolysis. South Med J. Teicoplanin nephrotoxicity: first case report. Minocycline-induced drug reaction with eosinophilia and systemic symptoms DRESS syndrome with persistent myocarditis.
J Am Acad Dermatol. Minocycline pneumonitis and eosinophilia. A report on eight patients. Arch Intern Med. Minocycline as possible cause of severe and protracted hypersensitivity drug reaction. Arch Dermatol. Pulmonary infiltrates with eosinophilia associated with tetracycline. Allergic rash due to amphotericin B.
Eosinophilic meningitis associated with ciprofloxacin. Feinmann L. Drug-induced lung disease: pulmonary eosinophilia and sulphonamides. Proc R Soc Med. Nitrofurantoin induced acute, subacute and chronic pulmonary reactions. A report of 66 cases. Scand J Resp Dis. Pulmonary toxicity of malaria prophylaxis. Pulmonary eosinophilia associated with dapsone. Ethambutol-induced pulmonary infiltrates with eosinophilia and skin involvement. Eur Respir J.
Lee M, Berger HW. Eosinophilia caused by rifampin. Eosinophilic colitis due to rifampicin. Intern Med. Eosinophilia during captopril treatment. Captopril, an angiotensin-converting enzyme inhibitor, induced pulmonary infiltration with eosinophilia. Rash, eosinophilia and hyperkalaemia associated with enalapril. Perindopril-associated pneumonitis. Eosinophilia associated with spironolactone. Drug-induced fever due to diltiazem.
Dukes MNG. Meylers side effects of drugs. Oxford: Elsevier Press; Eosinophilia caused by low-molecular-weight heparin. An Med Interna. Myocarditis related to drug hypersensitivity. Mayo Clin Proc. Bacon HM.
Eosinophilia associated with chlorpromazine therapy. Am J Psychiatry. Shear MK. Chlorpromazine-induced PIE syndrome. Adverse hematological effects in drug-induced dysfunction in psychiatry. New York: Hemisphere Publishing Corporation; Amsterdam JD. Int Clin Psychopharmacol. Eosinophilic pneumonia and respiratory failure associated with a trazodone overdose.
Jaundice and eosinophilia associated with amitriptyline. J Clin Psychiatry. Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia-myalgia syndrome. L-Tryptophan Optimax : limited availability for resistant depression. Current Problems in Pharmacovigilance. Clinical follow-up and immunogenetic studies of 32 patients with eosinophilia-myalgia syndrome.
Eosinophilia-myalgia syndrome: results of national surveillance. Weber RW. Adverse drug effects and the spectrum of eosinophilic pulmonary disorders. Ann Allergy Asthma Immunol. Carbamazepine and fatal eosinophilic myocarditis. N Engl J Med. Phenytoin-induced acute respiratory failure with pulmonary eosinophilia. Eosinophilic pleural effusion associated with valproic acid administration.
A case of eosinophilic pneumonia and vasculitis induced by diflunisal. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia: review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Diclofenac Voltaren -induced eosinophilic pneumonitis: case report and review of the literature. Eosinophilic meningitis and ibuprofen therapy. Clark, M. Maurer et al. Kay, S. Ying, E. Ardelean et al. Ito, T. Satoh, K. Takayamaet al.
Schadendorf, N. Haas et al. Allergy Immunol. Bruske, M. Standl, S. Weidinger et al. Khakoo, A. Sofianou-Katsoulis, M. Perkin et al. Hiragun, T. Hiragun, S. Miharaet al. Sahiner, E. Civelek, A. Tuncer et al. Zitelli K. Evidence-based evaluation and management of chronic urticaria in children. Caffarelli, B. Cuomo, F. Cardinale et al. Pite, B. Wedi, L. Borrego et al. IgE-mediated food allergy in children.
Novembre, A. Cianferoni, F. Mori et al. Greaves M. Monfrecola, E. Masturzo, A. Riccardo et al. Luong K. Allergy Asthma Immunol. Imbalzano, M. Casciaro, S. Quartuccio et al. Minciullo, A. Cascio, G. Barberiet al. Wustlich, R. Brehler, T. Luger et al. Akelma, M. Cizmeci, E. Mete et al.
Kolkhir, G. Balakirski, H. Merket al. Hill D. Philadelphia, ChurchillLivingstone, Khan, M. Konstantinou, R. Asero, M. Ferrer et al. Sabroe, P. Seed, D. Francis et al. Gaig, P. Garcia-Ortega, E. Enrique et al. Zauli, G. Deleonarid, S. Goderaro et al. Kowalski M. Grattan, D. Francis, N. Slater et al. A Popular myth — low-histamine diet improves chronic spontaneous urticaria— fact or fiction? Wagner, D. Dirk, A.
Journal of Investigational Allergology and Clinical Immunology is indexed/abstracted in Chemical Abstracts, Current Biology, Current Contents – Clinical. Journal of Investigational Allergology and Clinical Immunology should be cited as J Investig Allergol Clin Immunol for abstracting, indexing and referencing. I. Basic Journal Info · Country · Journal ISSN: · Publisher: Esmon Publicidad S.A. · History: ongoing · Journal Hompage: Link · How to Get Published.